Abstract
Abstract Cottontail rabbit papillomavirus (CRPV)/HLA-A2.1 transgenic rabbit infection model has been reported previously. Because the CRPV genome can be modified extensively without loss of its function, this transgenic rabbit model can be used for testing the specificity of host immunity to specific HLA-A2.1 restricted papillomavirus protein epitopes in vivo. In this study, we incorporated online MHCI epitope prediction software, HLA-A2.1 transgenic mouse and rabbit systems together to demonstrate an efficient way to identify and test immunogenicity of HLA-A2.1 restricted epitopes from CRPVE1 (161–169 LLFRQAHSV and 303–311 MLQEKPFQL). Both epitopes were able to induce specific cytotoxic CD8 T cells in HLA-A2.1 transgenic mice immunized with peptides. Using an epitope DNA vaccination method, complete and partial protection against CRPV infection was achieved by CRPVE1/303–311 and CRPVE1/161–169 in HLA-A2.1 transgenic rabbits respectively. Our data further demonstrated the application of HLA-A2.1 transgenic rabbits as a potential in vivo model system to test papillomavirus therapeutic vaccines.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
